公开(公告)号：US20190142842A1

公开(公告)日：2019-05-16

申请号：US16243842

申请日：2019-01-09

Applicant: ForSight Vision5, Inc.

Inventor： Logan Stark ,  Rachna Jain ,  Ravi Srinivasan ,  Cary J. Reich ,  Carlos Schuler

IPC: A61K31/5575 ,  A61K9/00 ,  A61K47/34

Abstract: The present disclosure includes compositions of a semi-crystalline or crystalline pharmaceutically active agent dispersed in a polymer matrix, in which the active agent is less degraded and, therefore, has lower level of impurities. The present disclosure further includes a method of reducing or preventing physical and chemical degradation of a semi-crystalline or crystalline active agent pharmaceutically active agent dispersed in a polymer matrix. A method of preparation of the composition is also included in this disclosure.

公开(公告)号：US20180085254A1

公开(公告)日：2018-03-29

申请号：US15694079

申请日：2017-09-01

Applicant: ForSight Vision5, Inc.

Inventor： Anne Brody Rubin ,  Yair Alster ,  Cary J. Reich

IPC: A61F9/00

CPC classification number: A61F9/0017 ,  A61F2250/0067

Abstract: Disclosed is an ocular device including a first structure formed of a first material providing a first shape to the ocular device prior to positioning the ocular device on the surface of the eye, a second structure formed of a second, different material having a tubular structure and a lumen through which the first structure extends, and at least one therapeutic agent is dispersed within the second material of the second structure. The first shape of the ocular device conforms to a second, different shape after positioning the ocular device on the surface of the eye. Upon being removed from the eye, the ocular device retains the second shape or changes to a third shape different from both the first shape and the second shape. Related apparatus, systems and method are described.

公开(公告)号：US09750636B2

公开(公告)日：2017-09-05

申请号：US14063571

申请日：2013-10-25

Applicant: ForSight Vision5, Inc.

Inventor： Anne Brody Rubin ,  Yair Alster ,  Cary J. Reich

IPC: A61F9/00

CPC classification number: A61F9/0017 ,  A61F2250/0067 ,  Y10T156/1036

Abstract: Disclosed is an ocular device including a first structure formed of a first material providing a first shape to the ocular device prior to positioning the ocular device on the surface of the eye, a second structure formed of a second, different material having a tubular structure and a lumen through which the first structure extends, and at least one therapeutic agent is dispersed within the second material of the second structure. The first shape of the ocular device conforms to a second, different shape after positioning the ocular device on the surface of the eye. Upon being removed from the eye, the ocular device retains the second shape or changes to a third shape different from both the first shape and the second shape. Related apparatus, systems and method are described.

公开(公告)号：US10456293B2

公开(公告)日：2019-10-29

申请号：US15694079

申请日：2017-09-01

Applicant: ForSight Vision5, Inc.

Inventor： Anne Brody Rubin ,  Yair Alster ,  Cary J. Reich

IPC: A61F9/00

Abstract: Disclosed is an ocular device including a first structure formed of a first material providing a first shape to the ocular device prior to positioning the ocular device on the surface of the eye, a second structure formed of a second, different material having a tubular structure and a lumen through which the first structure extends, and at least one therapeutic agent is dispersed within the second material of the second structure. The first shape of the ocular device conforms to a second, different shape after positioning the ocular device on the surface of the eye. Upon being removed from the eye, the ocular device retains the second shape or changes to a third shape different from both the first shape and the second shape. Related apparatus, systems and method are described.

公开(公告)号：US10004636B2

公开(公告)日：2018-06-26

申请号：US15230275

申请日：2016-08-05

Applicant: Forsight Vision5, Inc.

Inventor： Yair Alster ,  Eugene de Juan, Jr. ,  Cary J. Reich ,  Stephen Boyd ,  David Sierra ,  Jose D. Alejandro ,  K. Angela Macfarlane ,  Douglas Sutton

IPC: A61F9/00 ,  A61M35/00 ,  A61K9/00 ,  A61K31/19 ,  A61K31/407 ,  A61K31/4178 ,  A61K31/5377 ,  A61K31/5415 ,  A61K31/43 ,  A61K31/55 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/56 ,  A61K31/568 ,  A61K31/573 ,  A61K31/58 ,  A61K31/7036 ,  A61K38/00 ,  A61M31/00 ,  A61K31/335

CPC classification number: A61F9/0026 ,  A61F9/0017 ,  A61K9/0051 ,  A61K31/19 ,  A61K31/335 ,  A61K31/407 ,  A61K31/4178 ,  A61K31/43 ,  A61K31/5377 ,  A61K31/5415 ,  A61K31/55 ,  A61K31/557 ,  A61K31/5575 ,  A61K31/56 ,  A61K31/568 ,  A61K31/573 ,  A61K31/58 ,  A61K31/7036 ,  A61K38/00 ,  A61M31/002

Abstract: A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.

公开(公告)号：US20180092926A1

公开(公告)日：2018-04-05

申请号：US15725145

申请日：2017-10-04

Applicant: ForSight Vision5, Inc.

Inventor： Cary J. Reich ,  Carlos Schuler ,  Qiang Ye ,  Logan Stark ,  Rachna Jain

IPC: A61K31/5575 ,  A61L27/18 ,  A61L27/54 ,  A61L27/48 ,  A61F9/00 ,  A61K47/34 ,  A61K9/70 ,  A61K9/00 ,  C08L83/04

CPC classification number: A61K31/5575 ,  A61F9/0017 ,  A61K9/0051 ,  A61K9/70 ,  A61K47/34 ,  A61L27/18 ,  A61L27/48 ,  A61L27/54 ,  C08L83/04

Abstract: The present invention is directed to compositions of bimatoprost, processes of preparing these compositions, devices comprising these compositions, and methods of lowering intraocular pressure.

公开(公告)号：US20230181356A1

公开(公告)日：2023-06-15

申请号：US17869265

申请日：2022-07-20

Applicant: ForSight Vision5, Inc.

Inventor： Anne Brody Rubin ,  Yair Alster ,  Cary J. Reich

IPC: A61F9/00

CPC classification number: A61F9/0017 ,  A61F2250/0067 ,  Y10T156/1036

Abstract: Disclosed is an ocular device including a first structure formed of a first material providing a first shape to the ocular device prior to positioning the ocular device on the surface of the eye, a second structure formed of a second, different material having a tubular structure and a lumen through which the first structure extends, and at least one therapeutic agent is dispersed within the second material of the second structure. The first shape of the ocular device conforms to a second, different shape after positioning the ocular device on the surface of the eye. Upon being removed from the eye, the ocular device retains the second shape or changes to a third shape different from both the first shape and the second shape. Related apparatus, systems and method are described.

公开(公告)号：US20220331336A1

公开(公告)日：2022-10-20

申请号：US17542838

申请日：2021-12-06

Applicant: ForSight Vision5, Inc.

Inventor： Logan Stark ,  Rachna Jain ,  Ravi Srinivasan ,  Cary J. Reich ,  Carlos Schuler

IPC: A61K31/5575 ,  A61K9/00 ,  A61K47/34

Abstract: The present disclosure includes compositions of a semi-crystalline or crystalline pharmaceutically active agent dispersed in a polymer matrix, in which the active agent is less degraded and, therefore, has lower level of impurities. The present disclosure further includes a method of reducing or preventing physical and chemical degradation of a semi-crystalline or crystalline active agent pharmaceutically active agent dispersed in a polymer matrix. A method of preparation of the composition is also included in this disclosure.

公开(公告)号：US10736774B2

公开(公告)日：2020-08-11

申请号：US16003857

申请日：2018-06-08

Applicant: ForSight Vision5, Inc.

Inventor： Yair Alster ,  Eugene de Juan, Jr. ,  Cary J. Reich ,  Stephen Boyd ,  David Sierra ,  Jose D. Alejandro ,  K. Angela Macfarlane ,  Douglas Sutton

IPC: A61F9/00 ,  A61K31/55 ,  A61K31/5377 ,  A61K31/5575 ,  A61K31/407 ,  A61K31/58 ,  A61K38/00 ,  A61K31/5415 ,  A61K31/43 ,  A61K31/19 ,  A61K31/557 ,  A61K31/4178 ,  A61K31/7036 ,  A61K31/573 ,  A61K31/568 ,  A61K9/00 ,  A61M31/00 ,  A61K31/335 ,  A61K31/56

Abstract: A therapeutic system comprises an ocular insert placed on a region outside an optical zone of an eye. The ocular insert comprises two structures: a first skeletal structure and a second cushioning structure. The first structure functions as a skeletal frame which maintains positioning of the implant along the anterior portion of the eye and provides support to the second, cushioning structure. This first structure maintains the attachment of the therapeutic system to the anterior portion of the eye for at least thirty days. In some embodiments the first structure remains a constant size and shape, e.g. a ring shape, a ring with haptics, or a curvilinear ring that is confined to and restrainingly engages the inferior and superior conjunctival fornices so as to retain the implant within the tear fluid and/or against the tissues of the eye.

公开(公告)号：US20200038240A1

公开(公告)日：2020-02-06

申请号：US16599828

申请日：2019-10-11

Applicant: ForSight Vision5, Inc.

Inventor： Eugene de Juan, Jr. ,  Yair Alster ,  Cary J. Reich ,  K. Angela Macfarlane ,  Janelle Chang ,  Stephen Boyd ,  David Sierra ,  Jose D. Alejandro ,  Douglas Sutton ,  Alexander J. Gould

IPC: A61F9/00 ,  A61L27/16 ,  A61L27/02 ,  A61B17/00 ,  A61K9/00

Abstract: A comfortable insert comprises a retention structure sized for placement under the eyelids and along at least a portion of conjunctival sac of the upper and lower lids of the eye. The retention structure resists deflection when placed in the conjunctival sac of the eye and to guide the insert along the sac when the eye moves. The retention structure can be configured in many ways to provide the resistance to deflection and may comprise a hoop strength so as to urge the retention structure outward and inhibit movement of the retention structure toward the cornea. The insert may move rotationally with deflection along the conjunctival sac, and may comprise a retention structure having a cross sectional dimension sized to fit within folds of the conjunctiva. The insert may comprise a release mechanism and therapeutic agent to release therapeutic amounts of the therapeutic agent for an extended time.